Linked Life Data

782692

Source:http://linkedlifedata.com/resource/pubmed/id/782692

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1976-11-1
pubmed:abstractText
A synthetic analog of gonadoliberin (gonadtropin-releasing factor of luteinizing hormone/follicle-stimulating hormone-releasing hormone), designated A-43818, was evaluated for its ability to effect regression of carcinogen-induced mammary tumors in the Sprague-Dawley rat. This analog, specifically (D-leuyl6, desglycyl-NH210, prolyl ethylamide9), gonadoliberin, is a potent synthetic luteinizing hormone/follicle-stimulating hormone-releasing hormone at low dose levels but, at the higher dose levels used in these studies, the effect appears to be that of a potent gonadoliberin antagonist. Administration of 5 or 20 mug of A-43818 per day to tumor-bearing rats was essentially as effective as ovariectomy in causing mammary tumor regression. At least 80% of the tumors in the A-43818-treated animals underwent regression; about one-half of the regressing tumors disappeared in the 6-week period of continuous treatment, and, unlike the 0.9% NaCl solution control group, no new tumors appeared during the treatment period. A subsequent 4-week period of drug withdrawal resulted in the regrowth of palpable tumors and the appearance of new tumors, most of which again regressed on further A-43818 administration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0008-5472
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3830-3
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1976
pubmed:articleTitle
Regression of rat mammary tumors effected by a gonadoliberin analog.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.